Kreissl MC - Search Results

1

Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer.

Kreissl MC, Janssen MJR, Nagarajah J. Kreissl MC, et al. J Nucl Med. 2019 Jan;60(1):9-15. doi: 10.2967/jnumed.117.190819. Epub 2018 Sep 6. J Nucl Med. 2019. PMID: 30190306 Free article. Review.

2

Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.

Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M. Verburg FA, et al. Among authors: kreissl mc. Eur J Nucl Med Mol Imaging. 2010 May;37(5):896-903. doi: 10.1007/s00259-009-1303-x. Epub 2009 Dec 24. Eur J Nucl Med Mol Imaging. 2010. PMID: 20033685

3

Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.

Kreissl MC, Fassnacht M, Mueller SP. Kreissl MC, et al. Nuklearmedizin. 2015;54(3):88-93. Nuklearmedizin. 2015. PMID: 26105716 Review.

4

The Treatment of Well-Differentiated Thyroid Carcinoma.

Paschke R, Lincke T, Müller SP, Kreissl MC, Dralle H, Fassnacht M. Paschke R, et al. Among authors: kreissl mc. Dtsch Arztebl Int. 2015 Jun 26;112(26):452-8. doi: 10.3238/arztebl.2015.0452. Dtsch Arztebl Int. 2015. PMID: 26205749 Free PMC article. Review.

5

Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.

Werner RA, Lückerath K, Schmid JS, Higuchi T, Kreissl MC, Grelle I, Reiners C, Buck AK, Lapa C. Werner RA, et al. Among authors: kreissl mc. Sci Rep. 2016 Jun 16;6:28081. doi: 10.1038/srep28081. Sci Rep. 2016. PMID: 27306607 Free PMC article.

6

Predictive Value of ¹⁸F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib.

Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl MC, Lapa C. Werner RA, et al. Among authors: kreissl mc. J Nucl Med. 2018 May;59(5):756-761. doi: 10.2967/jnumed.117.199778. Epub 2017 Oct 12. J Nucl Med. 2018. PMID: 29025983 Free article.

7

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J, Kreissl M, Aller J, Grande E. Capdevila J, et al. Cancer Treat Rev. 2018 Sep;69:164-176. doi: 10.1016/j.ctrv.2018.06.019. Epub 2018 Jul 2. Cancer Treat Rev. 2018. PMID: 30032061 Review.

8

Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.

Verburg FA, Amthauer H, Binse I, Brink I, Buck A, Darr A, Dierks C, Koch C, König U, Kreissl MC, Luster M, Reuter C, Scheidhauer K, Willenberg HS, Zielke A, Schott M. Verburg FA, et al. Among authors: kreissl mc. Horm Metab Res. 2021 Mar;53(3):149-160. doi: 10.1055/a-1380-4154. Epub 2021 Mar 2. Horm Metab Res. 2021. PMID: 33652491 Free PMC article. Review.

9

[Therapy concepts for thyroid carcinoma].

Eilsberger F, Kreissl MC, Luster M, Pfestroff A. Eilsberger F, et al. Among authors: kreissl mc. Nuklearmedizin. 2022 Jun;61(3):223-230. doi: 10.1055/a-1650-9762. Epub 2022 Jun 3. Nuklearmedizin. 2022. PMID: 34644802 German.

10

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.

Kaae AC, Kreissl MC, Krüger M, Infanger M, Grimm D, Wehland M. Kaae AC, et al. Among authors: kreissl mc. Int J Mol Sci. 2021 Nov 12;22(22):12217. doi: 10.3390/ijms222212217. Int J Mol Sci. 2021. PMID: 34830100 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page